Literature DB >> 21327823

Association of elevated HIF-2α levels with low Beclin 1 expression and poor prognosis in patients with chondrosarcoma.

Changbao Chen1, Qingjun Ma, Xinlong Ma, Zhongjun Liu, Xiaoguang Liu.   

Abstract

BACKGROUND: Hypoxia inducible factor (HIF)-2α is an important transcription factor that contributes to tumor proliferation and progression. Beclin 1 is a key mediator of autophagy, and dysfunction of Beclin 1 is implicated in tumorigenicity. This study was designed to investigate the expression patterns of HIF-2α and Beclin 1 and to clarify their clinical significance in chondrosarcoma.
METHODS: The mRNA and protein levels of HIF-2α and Beclin 1 in chondrosarcoma and the corresponding nontumor tissues were analyzed by real-time polymerase chain reaction and Western blot, respectively. The protein expression of HIF-2α and Beclin 1 was investigated by immunohistochemistry, and their associations with clinicopathological factors and overall survival were evaluated.
RESULTS: HIF-2α was remarkably elevated, whereas Beclin 1 was significantly reduced in chondrosarcoma compared with the corresponding nontumor tissues. High HIF-2α level and negative Beclin 1 expression were 52.9% and 58.8% in chondrosarcoma specimens, respectively. HIF-2α and Beclin 1 were associated with histological grade and Musculoskeletal Tumor Society stage. There was a significant inverse relationship between HIF-2α and Beclin 1. HIF-2α and Beclin 1 had significant impacts on the prognosis of chondrosarcoma patients. Multivariate analysis revealed that Beclin 1 was an independent prognostic factor for overall survival of patients with chondrosarcoma.
CONCLUSIONS: Elevated HIF-2α levels associated with low Beclin 1 expression play a role in the development of chondrosarcoma. Beclin 1 can serve as a novel biomarker to predict survival of chondrosarcoma patients, and may represent a potential therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21327823     DOI: 10.1245/s10434-011-1587-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  18 in total

Review 1.  Genetic alterations in chondrosarcomas - keys to targeted therapies?

Authors:  Andre M Samuel; Jose Costa; Dieter M Lindskog
Journal:  Cell Oncol (Dordr)       Date:  2014-01-24       Impact factor: 6.730

2.  Description of the immune microenvironment of chondrosarcoma and contribution to progression.

Authors:  François A Simard; Iseulys Richert; Alexandra Vandermoeten; Anne-Valérie Decouvelaere; Jean-Philippe Michot; Christophe Caux; Jean-Yves Blay; Aurélie Dutour
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

Review 3.  The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness.

Authors:  Bin Bao; Asfar S Azmi; Shadan Ali; Aamir Ahmad; Yiwei Li; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2012-05-10

4.  Elevated levels of Dickkopf-1 are associated with β-catenin accumulation and poor prognosis in patients with chondrosarcoma.

Authors:  Changbao Chen; Hua Zhou; Xiaolin Zhang; Xinlong Ma; Zhongjun Liu; Xiaoguang Liu
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

5.  Dysregulation of Zinc Finger Protein 395 Contributes to the Pathogenesis of Chondrosarcoma.

Authors:  Changbao Chen; Hua Zhou; Zhongjun Liu; Xinlong Ma
Journal:  Onco Targets Ther       Date:  2021-06-01       Impact factor: 4.147

Review 6.  Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence.

Authors:  Jeffrey I Traylor; Mark N Pernik; Aaron R Plitt; Michael Lim; Tomas Garzon-Muvdi
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

7.  Identification of ZNF704 as a Novel Oncogene and an Independent Prognostic Marker in Chondrosarcoma.

Authors:  Changbao Chen; Hua Zhou; Xiaolin Zhang; Zhongjun Liu; Xinlong Ma
Journal:  Cancer Manag Res       Date:  2021-06-21       Impact factor: 3.989

8.  Expression of autophagy-related protein Beclin-1 in malignant canine mammary tumors.

Authors:  Jing-Lan Liu; Kai-Chian Chang; Chun-Chih Lo; Pei-Yi Chu; Chen-Hsuan Liu
Journal:  BMC Vet Res       Date:  2013-04-11       Impact factor: 2.741

9.  Hypoxia-inducible factors: mediators of cancer progression; prognostic and therapeutic targets in soft tissue sarcomas.

Authors:  Navid Sadri; Paul J Zhang
Journal:  Cancers (Basel)       Date:  2013-04-02       Impact factor: 6.639

10.  Expression of beclin 1 in primary salivary adenoid cystic carcinoma and its relation to Bcl-2 and p53 and prognosis.

Authors:  L C Jiang; S Y Huang; D S Zhang; S H Zhang; W G Li; P H Zheng; Z W Chen
Journal:  Braz J Med Biol Res       Date:  2014-01-29       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.